DVAX enters clinical trial for its COVID vaccine, sparking market optimism. As a leading biotech company, Dynavax Technologies' stock is on a steady upswing. Considered as one of the top stocks to buy for the next decade, DVAX joins other promising names like PLTR, AMD, RCAT, and LCID in the list of potential explosive growth stocks. VectorVest rates DVAX highly for its future potential.